Tracon Pharmaceuticals Inc (NASDAQ:TCON) CEO Charles Theuer sat down with Proactive’s Christine Corrado at the Biotech Showcase 2020 in San Francisco. The San Diego-based clinical stage biopharmaceutical company is focused on the development and commercialization of novel targeted therapeutics for cancer, age-related macular degeneration and fibrotic diseases.
Tracon Pharmaceuticals refills pipeline with newly licensed immune checkpoint inhibitor therapy
Quick facts: TRACON Pharmaceuticals
Price: 4.84 USD
Market Cap: $63.8 m
NO INVESTMENT ADVICE
The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...
In exchange for publishing services rendered by the Company on behalf of TRACON Pharmaceuticals named herein, including the promotion by the Company of TRACON Pharmaceuticals in any Content on the Site, the Company...FOR OUR FULL DISCLAIMER CLICK HERE